-
Mashup Score: 2
Cancer patients often ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Stanford University School of Medicine oncologist Pauline Funchain, MD, how she would handle her own diagnosis of advanced melanoma. (Note: This piece originally appeared in 2021; now, Dr. Funchain provides her updated expert perspective.) Curious Dr. George: What would you do if you personally were discovered… Read more »
Source: cancercommons.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48Germline Cancer Susceptibility in Individuals with Melanoma - 5 month(s) ago
Inherited melanoma is not rare: approximately 1 in 7 individuals with melanoma harbored clinically relevant hereditable cancer susceptibility in a prospective cross-sectional study, with 3 validation cohorts supporting 10-16% incidence. We recommend obtaining family history inclusive of non-cutaneous cancers and considering genetics referral for ≥2 melanomas/cancers to increase diagnostic yield.
Source: www.jaad.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 31Checkpoint NOW: Season 2: Episode 4: Adrenal Insufficiency- What patients need to know. on Apple Podcasts - 6 month(s) ago
Show Checkpoint NOW, Ep Season 2: Episode 4: Adrenal Insufficiency- What patients need to know. – Jul 7, 2024
Source: podcasts.apple.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma - 10 month(s) ago
AbstractPurpose:. Malignant melanoma represents the most lethal skin cancer with germline predispositions thought to comprise 10% to 15% of all melanoma cases. No studies to date examine the immunologic features that may differentiate survival differences between germline pathogenic variant (gPV)–positive patients with melanoma from gPV-negative patients with melanoma.Experimental Design:. Adult patients with melanoma and clinical characteristics suggesting hereditary predisposition to cancer were prospectively recruited to undergo germline testing and flow cytometric analysis of peripheral immune suppressor cells.Results:. In this cohort, gPV-positive patients (n = 72) had a significantly improved melanoma-specific survival (MSS) compared with gPV-negative patients (n = 411; HRadj, 0.32; 95% CI, 0.13–0.82; P = 0.01). These survival improvements among gPV-positive patients were most apparent among cutaneous melanoma subtypes (HRadj, 0.12; 95% CI, 0.016–0.86; P = 0.03) and numerically i
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 47Germline Cancer Susceptibility in Individuals with Melanoma - 10 month(s) ago
Inherited melanoma is not rare: approximately 1 in 7 individuals with melanoma harbored clinically relevant hereditable cancer susceptibility in a prospective cross-sectional study, with 3 validation cohorts supporting 10-16% incidence. We recommend obtaining family history inclusive of non-cutaneous cancers and considering genetics referral for ≥2 melanomas/cancers to increase diagnostic yield.
Source: www.jaad.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 52The Immune Related Adverse Events (irAE) Consortium - GHLF.org - 11 month(s) ago
Immunotherapy is an emerging treatment that gives hope to patients facing different types of cancer. It stimulates the body’s immune system to fight cancer cell
Source: GHLF.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48The Immune Related Adverse Events (irAE) Consortium - GHLF.org - 12 month(s) ago
Immunotherapy is an emerging treatment that gives hope to patients facing different types of cancer. It stimulates the body’s immune system to fight cancer cell
Source: GHLF.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Thieme E-Books & E-Journals
Source: www.thieme-connect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3
Next Generation Dx Summit, August 21-23, 2023, Washington, D.C.
Source: www.nextgenerationdx.comCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 1Advances in Cancer Immunotherapy Regional Education Programs - 2 year(s) ago
The SITC Advances in Cancer Immunotherapy (ACI) programs are CE- and MOC-accredited programs presented by local authorities in tumor immunology and cancer immunotherapy and are free for healthcare professionals, students and patient advocates.
Source: www.sitcancer.orgCategories: Hem/Oncs, Latest HeadlinesTweet
Imagining myself walking through a new diagnosis of metastatic melanoma - plain language advice to myself which I would hope can help someone out there orient, take a deep breath, and step forward. Cancer Commons with Curious Dr. George https://t.co/w0qsOH7CQi